Dear Editor, Uyar et al. investigated the association between estimated glomerular filtration rate (eGFR) and obstructive sleep apnea (OSA) in 634 OSA patients aged 18 years or older [1] . eGFR was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Sixty-two subjects without OSA (controls) were also set for the analysis. The authors observed that eGFR values were significantly lower in OSA patients with metabolic syndrome (MetS), hypertension, and/or left ventricular hypertrophy. I have some concerns on their study.
First, the authors did not conduct multivariate analysis with adjustment of confounders. As MetS was associated with renal dysfunction, they speculated that renal dysfunction was derived from OSA and/or MetS. I think that comprehensive analyses with enough number of subjects would make stable risk assessment possible. On this point, Ogna et al. evaluated the association between early stages of CKD and sleep disordered breathing (SDB), restless legs syndrome (RLS), and subjective and objective sleep quality (SQ) in 1760 adults with sleep polysomnography at home [2] . They adopted multivariate logistic or linear regression analyses. Patients with early stages of CKD have impaired SQ, use more hypnotic drugs, and have an increased prevalence of SDB and PLM, but significant association with declining kidney function was only observed in objective SQ and PLMI by controlling for confounders. Namely, association between SDB/OSA and renal function was weak and not always observed. Although biological mechanism on the association would be complicated, a follow-up study or an interventional study should be conducted to confirm causal association.
Relating to the first query, Chen et al. conducted a metaanalysis on the effect of positive airway pressure (PAP) on GFR in patients with SDB [3] . Although there was no change of GFR before and after PAP treatment in SDB patients, subgroup analyses presented a significant improvement of GFR in patients aged 55 years or older and patients with therapeutic duration of 3 months or longer.
Second, mean value of eGFR in their study did not decrease significantly according to the severity of OSA. In addition, mean value eGFR in patients with OSA was 90.74 ml/ min/1.73 m 2 in males and 87.73 ml/min/1.73 m 2 in females. I suppose that the authors handled patients without severe chronic renal disease. The association should also be evaluated by considering the severity of CKD in further study.
